α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. - Wikidata - awgldk - TriplyDB

α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons.

α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons.

http://www.wikidata.org/entity/Q34503671

about

Neuroprotective Transcription Factors in Animal Models of Parkinson Disease Merging DBS with viral vector or stem cell implantation: "hybrid" stereotactic surgery as an evolution in the surgical treatment of Parkinson's disease Parkinson's disease gene therapy: success by design meets failure by efficacy Maintenance of postmitotic neuronal cell identity Treating Parkinson's disease in the 21st century: can stem cell transplantation compete?Comparative Analysis of the Effects of Neurotrophic Factors CDNF and GDNF in a Nonhuman Primate Model of Parkinson's Disease Elevated α-synuclein caused by SNCA gene triplication impairs neuronal differentiation and maturation in Parkinson's patient-derived induced pluripotent stem cells GDNF-Ret signaling in midbrain dopaminergic neurons and its implication for Parkinson disease Formation of α-synuclein Lewy neurite-like aggregates in axons impedes the transport of distinct endosomes.Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease Novel AAV-based rat model of forebrain synucleinopathy shows extensive pathologies and progressive loss of cholinergic interneurons Nuclear receptors in neurodegenerative diseases.The N-terminal region of Nurr1 (a.a 1-31) is essential for its efficient degradation by the ubiquitin proteasome pathway.Functional neuroprotection and efficient regulation of GDNF using destabilizing domains in a rodent model of Parkinson's disease.Correlation between orphan nuclear receptor Nurr1 expression and amyloid deposition in 5XFAD mice, an animal model of Alzheimer's disease.NURR1 in Parkinson disease--from pathogenesis to therapeutic potential.Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism.Can Parkinson's disease be cured by stimulating neurogenesis?A Nurr1 agonist causes neuroprotection in a Parkinson's disease lesion model primed with the toll-like receptor 3 dsRNA inflammatory stimulant poly(I:C).High Throughput Sequencing Identifies MicroRNAs Mediating α-Synuclein Toxicity by Targeting Neuroactive-Ligand Receptor Interaction Pathway in Early Stage of Drosophila Parkinson's Disease Model.Combined Nurr1 and Foxa2 roles in the therapy of Parkinson's disease.Parkin cooperates with GDNF/RET signaling to prevent dopaminergic neuron degeneration CD24 expression does not affect dopamine neuronal survival in a mouse model of Parkinson's disease.Cyclosporin promotes neurorestoration and cell replacement therapy in pre-clinical models of Parkinson's disease A regulatable AAV vector mediating GDNF biological effects at clinically-approved sub-antimicrobial doxycycline doses.Nurr1-Based Therapies for Parkinson's Disease.Selective brain penetrable Nurr1 transactivator for treating Parkinson's disease.Altered dopamine ontogeny in the developmentally vitamin D deficient rat and its relevance to schizophrenia Transcription factor Six2 mediates the protection of GDNF on 6-OHDA lesioned dopaminergic neurons by regulating Smurf1 expression.Transcriptional activity of novel ALDH1L1 promoters in the rat brain following AAV vector-mediated gene transfer Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.Gene Therapy: A Promising Approach for Neuroprotection in Parkinson's Disease?RNA Interference of Human α-Synuclein in Mouse.Exposure to atrazine during gestation and lactation periods: toxicity effects on dopaminergic neurons in offspring by downregulation of Nurr1 and VMAT2 In vitro generation of mature midbrain-type dopamine neurons by adjusting exogenous Nurr1 and Foxa2 expressions to their physiologic patterns.Glial Cell Line-Derived Neurotrophic Factor Gene Delivery in Parkinson's Disease: A Delicate Balance between Neuroprotection, Trophic Effects, and Unwanted Compensatory Mechanisms.Therapeutic prospects for Parkinson disease.Animal models of Parkinson's disease: a gateway to therapeutics?Models of α-synuclein aggregation in Parkinson's disease.Viral vector delivery of neurotrophic factors for Parkinson's disease therapy.

P2860

Q26765693-BB0FB156-AF02-4627-9B47-7826FC30E010 Q26773485-7C5C53A6-A44C-4391-A154-253E8E47D96B Q26851325-2AF24DB5-FE78-49CE-8833-A7A75C028261 Q27010931-2B8FD3A8-CA67-48D3-A9DB-B14E8DF0C1CA Q27024152-66FC1DF3-7C44-4067-A8A5-361EE34F084E Q27320553-F4601BB2-47FF-429E-9AC4-C5C780ACE259 Q27329722-285BEECD-DC8B-4FF8-9A5A-539675820D6B Q28083626-36639FFF-DA62-42CD-9E64-0B837E772D49 Q30607522-EFB84BD5-0F05-4F1F-913A-053684A3FF66 Q30833636-31498EFE-72C4-433A-BCED-BAF26D827580 Q33856698-90D2D721-43C1-47A3-86F4-B6D49080D49E Q34580020-FDFBC52B-53B2-4E68-9F1A-79704CF49BAB Q34586538-DE1F04B2-CF67-44D0-9078-CBE1FA0597CE Q34861724-5F7CF77A-D1F1-4D80-BBBD-4D307D458D03 Q34995704-BACB44F9-DD2E-4826-BCB9-8C7223C267BF Q35017493-70BCB3F6-6110-40B0-842E-ECEE81569C0B Q35154720-EBDD5DE5-A026-4907-B156-A8F8C3CF812E Q35183991-0E27CE76-DD9F-4AFD-864B-CFF91F331633 Q35224798-BC065829-19C2-4F13-8439-F5475DE28825 Q35771016-70B9315C-0005-43B6-ADCD-FB5499481EDB Q35822548-29DDC509-D74A-4285-8098-D574781B1E85 Q36179023-F7BDDFFC-3E98-4DD4-8E43-767A466E15E6 Q36275740-0FB02C13-E862-4BE7-89C4-403237BCE707 Q36370618-588F3922-796D-4F26-AAAD-E028B635878F Q36744851-A99B0EA0-DE81-4895-BEB3-F443C147E243 Q36803630-D045A387-58E9-431D-89CE-CDE2508148C9 Q36946543-1A26AF0C-D462-490E-9AC3-91C9B8D7878F Q37019129-468B9767-552C-41A8-BEA8-D48E54B38685 Q37030300-99329E1A-EA13-458E-9F38-D27BEB54C5EC Q37458119-017DAB3E-0B82-4BF0-ADF9-B46BA3FE5CEE Q37506492-5B084946-8F3E-4AD6-8844-7594A626D7DE Q37516424-23E37A57-B270-4A45-A80E-E14752E81166 Q37614503-985995AE-CFA6-4A21-B6A0-FE4B7224B442 Q37645320-1812AC8B-B1AC-497B-BD3A-13B48A3CE39C Q37739466-6CC2FBEC-BAE0-48FE-AB7D-C1B5E4BB196F Q37742852-866BDA5A-0DCE-4173-B3A5-4D2DE6B5AD5C Q38137889-DF8A5549-5506-4255-AACA-A3B61A6A8F35 Q38155480-4672A107-A2B8-46BF-808E-5DBFE19E071E Q38286574-1DA09968-EA0F-4153-9786-E77C07DA2B5D Q38495722-1ACC79F0-4EFF-45D4-BC06-D7285ABAA451

P2860

α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons.

http://www.wikidata.org/entity/Q34503671

description

2012 nî lūn-bûn

@nan

2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

α-Synuclein-induced down-regul ...... ng in nigral dopamine neurons.

@ast

α-Synuclein-induced down-regul ...... ng in nigral dopamine neurons.

@en

α-Synuclein-induced down-regul ...... ng in nigral dopamine neurons.

@nl

type

label

α-Synuclein-induced down-regul ...... ng in nigral dopamine neurons.

@ast

α-Synuclein-induced down-regul ...... ng in nigral dopamine neurons.

@en

α-Synuclein-induced down-regul ...... ng in nigral dopamine neurons.

@nl

prefLabel

α-Synuclein-induced down-regul ...... ng in nigral dopamine neurons.

@ast

α-Synuclein-induced down-regul ...... ng in nigral dopamine neurons.

@en

α-Synuclein-induced down-regul ...... ng in nigral dopamine neurons.

@nl

P1433

Q34503671-2BA4C0B0-1226-4D20-B6BF-91DC1296AA6E

P1476

Q34503671-2A69290C-5C0B-4455-AF79-6BA4411E3316

P2093

Q34503671-86CF0989-482F-4689-B3E0-D121DC10FD2A

Q34503671-8C9074F4-8012-4E8A-A0FF-36300E5298FB

Q34503671-A6323A86-B99A-4284-BDAF-43BBEB0A43C4

Q34503671-B68EFD86-506F-4466-B0F6-476FF5465CEA

Q34503671-E6851EA5-F7FF-4971-9245-05B74FAD5903

P2860

Q34503671-0026AACD-670C-4044-9FC7-4C9DB667DA02

Q34503671-03F5F8C9-47AE-4229-8454-F5959345B2F3

Q34503671-047AB685-6DD4-4719-87C1-0AC4BD8CB6F8

Q34503671-06BDD23F-0F97-4CC1-99F8-B7FF499109CC

Q34503671-07B27871-F284-496D-8390-386EE8871115

Q34503671-0B99636B-9504-4D70-960D-BED8D3383E95

Q34503671-0F74108C-E3E6-4D0A-A3AA-66E33166805D

Q34503671-1E9871F9-3292-4B80-8C2D-43B9074A4E17

Q34503671-2102AA5D-4E38-4A65-9B65-D7985EA4358C

Q34503671-23609E4E-15AD-4605-AD15-9F0308F353A9

P304

Q34503671-B60D4BB6-07B0-4AA3-9E5B-F6EE169BC297

P31

Q34503671-5E651416-7724-42E0-8FB7-3C588A45F27F

P356

Q34503671-D0991288-EBFA-4B23-BC9B-51C9C86C03DF

P407

Q34503671-BEBE3C8E-B3A1-4663-9945-67E3ED3697CA

P433

Q34503671-A157714B-0B90-4571-91E7-A80AB4428645

P478

Q34503671-39E63756-E463-4B51-AFF6-5531C50FC3E3

P50

Q34503671-741254DB-3633-4D5D-877E-8F317373734D

P577

Q34503671-9BC8963E-762A-4CBC-A8F8-EBC83A73B27B

P5875

Q34503671-5CE93610-AEB0-43A0-BF21-26740388D593

P698

Q34503671-FFA47993-51E4-4553-BC59-8B67A3838CFF

P921

Q34503671-BF27A084-3764-4207-B5F3-D2153E4F39A2

Q34503671-a3f97920-7998-4fe3-bec7-c828c8329d3a

P356

SCITRANSLMED.3004676

P1433

Science Translational Medicine

P1476

α-Synuclein-induced down-regul ...... ng in nigral dopamine neurons.

@en

P2093

Ariadna Laguna

http://www.w3.org/2001/XMLSchema#string

Banafsheh Kadkhodaei

http://www.w3.org/2001/XMLSchema#string

Bengt Mattsson

http://www.w3.org/2001/XMLSchema#string

Mickael Decressac

http://www.w3.org/2001/XMLSchema#string

Thomas Perlmann

http://www.w3.org/2001/XMLSchema#string

P2860

Absence of Ret signaling in mice causes progressive and late degeneration of the nigrostriatal system

miR-22 forms a regulatory loop in PTEN/AKT pathway and modulates signaling kinetics

Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity

Characterisation of a novel NR4A2 mutation in Parkinson's disease brain

MicroRNA-7 targets IGF1R (insulin-like growth factor 1 receptor) in tongue squamous cell carcinoma cells

Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS

Crossroads in GDNF therapy for Parkinson's disease

Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease

P304

163ra156

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.3004676

http://www.w3.org/2001/XMLSchema#string

P407

P433

163

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Anders Björklund

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233878763

http://www.w3.org/2001/XMLSchema#string

P698

23220632

http://www.w3.org/2001/XMLSchema#string

P921